NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
Clinical Trials
14 trialsNCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT01597908 2021-02-24
COMBI-v
Novartis
Phase 3 Completed
NCT01739764 2021-01-07
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Hoffmann-La Roche
Phase 4 Completed
NCT01767623 2018-02-13
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
Hoffmann-La Roche
Phase 1 Completed
NCT02441465 2017-11-14
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
Hoffmann-La Roche
Phase 1 Completed
NCT01765543 2016-12-15
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
Hoffmann-La Roche
Phase 1 Completed
NCT01849666 2016-11-02
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Hoffmann-La Roche
Phase 1 Completed
NCT01851824 2016-11-02
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Hoffmann-La Roche
Phase 1 Completed
NCT01974258 2016-11-02
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Hoffmann-La Roche
Phase 1 Withdrawn
NCT01286753 2016-09-07
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Hoffmann-La Roche
Phase 2 Completed
NCT01765569 2015-09-23
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01673737 2015-04-10
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
Sanofi
Phase 1 Completed